• How is RNA editing viewed by investors and what are the directions for growth?

• How to successfully gain funding for preclinical candidates by demonstrating the right data

• What are the hurdles and pitfalls to starting an RNA Editing therapeutics company and what are the timelines, collaborations, and levels of investment required